



Lintang Qusnul Budi Setiawati <lintangqusnulbs@gmail.com>

Fw: Peer Review Invitation Reminder [ID: 389197]

1 message

Prastiya Indra Gunawan <prastiya_ig@yahoo.co.id>
To: Lintang Qusnul Budi Setiawati <lintangqusnulbs@gmail.com>

Thu, Feb 23, 2023 at 11:58 PM

----- Pesan yang Diteruskan -----

Dari: Ms Gilbertson <fionagilbertson@dovepress.com>**Kepada:** Dr Gunawan <prastiya_ig@yahoo.co.id>**Terkirim:** Rabu, 28 September 2022 pukul 23.54.35 WIB**Judul:** Peer Review Invitation Reminder [ID: 389197]

Dear Dr Gunawan,

Recently we invited you to review the manuscript

Manuscript title: Severe Vincristine-Induced Neuropathic Pain: A Case Report with Pharmacogenetic Analysis and Literature Review

Article type: Case report

Author: Dr Hu

Journal: Pharmacogenomics and Personalized Medicine (Journal Impact Factor: 2.606)

We know that availability can be limited, and it is not always convenient to commit to completing a review. We have not heard from you regarding your willingness to review this manuscript, in order to expedite the review process, we will assume you are unable to review this paper at this time.

The journal relies on the quality of its expert peer reviewers such as yourself and we do hope you will be able to review other manuscripts for Pharmacogenomics and Personalized Medicine in the future.

Kind regards

Ms Gilbertson

On behalf of Dr Bluth

Manuscript ID number: 389197

Title of paper: Severe Vincristine-Induced Neuropathic Pain: A Case Report with Pharmacogenetic Analysis and Literature Review

Reviewed by: Dr Gunawan on 24 February 2023

Title & Abstract

1. Do the title and abstract cover the main aspect of the work?

Yes

Introduction

2. Does the introduction provide background and information relevant to the study? Please explain your decision.

Yes. The introduction appropriate with the idea

Case presented

3. Is the subject novel?

There is novelty of the case report . It has no ethical concerns

Discussion

4. Why is the case important?

The case is important for analyzing the risk factor of patient to become VIPN. Some factor related to the disease including polymorphism. the literature relevant to the case

Conclusion

5. Implication?

The case highlight the polymorphism in VIPN otherwise it does not change any advantages for the patient treatment. The case is too long better make it shorter with necessary findings and discussion

Figures & Tables

6. If the author has provided figures and tables are the figures and tables clear and legible? Are the figures free from unnecessary modification?

Yes

7. Does the paper raise any concerns?

No ethical concern

Competing interest

8. Do any of the authors' competing interests raise concerns about the validity of the study i.e. have the authors' competing interests created a bias in the reporting of the results and conclusions?

-

Recommendations to the Editor

9. Recommendations to Editors

Very good

10. Would you be willing to review a revision of this manuscript?

Yes

Additional comments

-

Confidential comments for Editor

-

Competing Interest Disclosure

none

Peer Reviewer Competing Interest Disclosure

-

To whom it may concern

Dr Prastiya Indra Gunawan has reviewed 1 submission in the journal *Pharmacogenomics and Personalized Medicine* (journal Impact Factor: 2.606) during 2022.

This contribution is greatly appreciated.

Regards

Angela Jones

General Manager, Dove Medical Press Ltd

Dove Medical Press (NZ) Ltd, 44 Corinthian Drive, Albany, Auckland, New Zealand

PO Box 300-008, Albany, Auckland, 0752, New Zealand

p +649 443 3060 **f** +649 443 3061 **e** info@dovepress.com

Live Chat https://www.dovepress.com/live_help.t

Twitter <https://twitter.com/DovePress>

www.dovepress.com - open access to scientific and medical research